SHTG Daily Digest — Weiss Lab

A quiet cycle on both fronts — one non-top-tier observational paper on pancreatitis recurrence in hypertriglyceridemia, and no fresh industry news beyond what's already been covered (Arrowhead's SHASTA-3/4 phase 3 data and the Ionis/Alnylam earnings stories all fell in prior episodes' windows).

A genuinely quiet cycle — the only new lipid-biology paper worth flagging is a human physiology study nailing down how ANGPTL3 deficiency reshapes triglyceride-rich lipoprotein clearance, while the industry side produced no fresh, previously-uncovered news on Arrowhead, Alnylam, or Ionis in the last five days.

It was a quiet week for new top-tier SHTG/ANGPTL/APOC3/LPL science, but Alnylam's 30% stock plunge on a surprise Amvuttra guidance cut is a reminder of how quickly sentiment can turn on RNAi-platform companies even as their lipid-focused programs (and rivals Ionis and Arrowhead) keep advancing on separate tracks.

It's a quiet cycle on both fronts — no new top-tier lipid papers cleared the bar, and the only notable industry item is a STAT News recap of the Arrowhead–Ionis triglyceride-drug rivalry that surfaces a previously undisclosed detail: Ionis's patent-infringement allegation against Arrowhead over the RNAi technology behind Redemplo (plozasiran).

A quiet cycle for new peer-reviewed lipid literature was overshadowed by Arrowhead Pharmaceuticals' Phase 3 plozasiran data in severe hypertriglyceridemia, which analysts are calling a "best-case scenario" that puts the drug on a collision course with Ionis's Tryngolza.

A quiet five days on both fronts — one dupe and one recycled news brief in the literature, and no fresh industry developments beyond the Tryngolza sHTG label expansion already covered last cycle.

It's a quiet cycle on both fronts — the only new PubMed entry is a review/perspective piece touching ANGPTL3 and apoC-III rather than primary data, and the industry side has nothing genuinely new since Tuesday's episode (Tryngolza's sHTG approval and related coverage were already covered in prior digests).

A quiet cycle on both fronts — Part A offers three next-tier papers on FCS-gene carrier states and the ANGPTL axis rather than any top-journal blockbuster, while Part B has no genuinely new news: the period's two biggest Ionis stories (the Tryngolza sHTG label expansion and the Wainua ATTR-CM trial failure) were both already covered in the July 10 episode and have no material updates since.

No top-tier journal papers cleared the bar this cycle so Part A drops down a tier to three directly relevant clinical items on hypertriglyceridemia and LPL biology, while Part B is dominated by a single but consequential Ionis story — the surprise Phase 3 failure of Wainua in ATTR-CM, which isn't a lipid-program readout but is reshaping the competitive and investor picture for Ionis and Alnylam.

A thin cycle on both sides — the only new top-tier hit is a review on residual lipid risk beyond LDL (ANGPTL/apoC-III/FGF21 pathways get a mention), and there's no fresh industry news in the last 5 days beyond last week's Tryngolza sHTG approval, which was already covered.